RET Fusion Targeted Therapies Market Set for Robust Growth by 2034 Amid Precision Oncology Shift | DelveInsight
The RET fusion-targeted therapy market is set for strong expansion, driven by growing awareness of the oncogenic role of RET gene fusions and encouraging clinical trial outcomes. With the approval of targeted agents such as selpercatinib and pralsetinib for RET fusion-positive tumors, oncology care is increasingly moving toward precision-driven approaches. Additionally, the launch of emerging therapies such as Sacituzumab tirumotecan (Merck & Co.), EP0031 (Ellipses Pharma), and others will further propel the market growth.
LAS VEGAS, Jan. 26, 2026 /PRNewswire/ -- DelveInsight's RET Fusion Targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as NSCLC, medullary thyroid cancer, and other cancers driven by RET fusions. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging RET fusion targeted therapies, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).
Key Takeaways from the RET Fusion Targeted Therapies Market Report
Discover how large is the eligible patient pool for RET fusion targeted therapies @ https://www.delveinsight.com/report-store/ret-fusion-market-forecast?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr
Key Factors Driving the RET Fusion Targeted Therapies Market
RET Fusion Targeted Therapies Market Analysis
Learn more about which drug has the largest market share in RET fusion therapies @ RET Fusion Targeted Therapies Analysis
RET Fusion Targeted Therapies Competitive Landscape
Some of the RET fusion targeted therapies in clinical trials include Sacituzumab tirumotecan (Merck & Co.), EP0031 (Ellipses Pharma), and others.
Merck & Co.'s Sacituzumab tirumotecan (MK-2870) is an investigational antibody–drug conjugate designed to target trophoblast cell-surface antigen 2 (TROP2), coupling a monoclonal antibody with a belotecan-based cytotoxic payload. The program is being co-developed with Sichuan Kelun-Biotech and has advanced to Phase III clinical evaluation in non-small cell lung cancer (NSCLC).
The ongoing Phase III trial is assessing sacituzumab tirumotecan versus standard chemotherapy options, including docetaxel or pemetrexed, in previously treated NSCLC patients harboring EGFR exon 19 deletions or exon 21 L858R mutations, as well as other oncogenic drivers such as ALK, ROS1, BRAF V600E, NTRK, MET exon 14 skipping mutations, RET rearrangements, and uncommon EGFR variants. The study is designed to determine therapeutic benefit across these molecularly defined subpopulations.
Ellipses Pharma's EP0031 is a next-generation, highly selective RET inhibitor currently being investigated in a Phase I/II clinical trial in adults with advanced solid tumors characterized by RET alterations, including NSCLC. At ASCO 2024, Phase I findings presented in May 2024 indicated a favorable safety and tolerability profile for EP0031. No dose-limiting toxicities or treatment-related fatalities were reported. Most treatment-emergent adverse events were mild to moderate (Grade 1–2), with only a limited number of Grade 3 events. Adverse events were generally manageable with temporary treatment interruptions, with no treatment discontinuations due to toxicity and only a small proportion of patients requiring dose reductions. These data support the continued clinical advancement of EP0031 in RET-driven cancers.
The anticipated launch of these emerging therapies are poised to transform the RET fusion targeted therapies market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the RET fusion targeted therapies market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about which companies are developing next-generation RET inhibitors, visit @ RET Fusion Targeted Therapies Treatment
What are RET Fusion Targeted Therapies?
RET fusion-targeted therapies are precision cancer treatments designed to inhibit signaling driven by rearranged during transfection (RET) gene fusions, which act as oncogenic drivers in multiple solid tumors. These fusions result from chromosomal rearrangements that constitutively activate the RET tyrosine kinase, promoting uncontrolled cell growth and survival. RET fusion-positive cancers are most commonly seen in non-small cell lung cancer (NSCLC) and thyroid cancers, but are also identified across a range of other solid tumors. Targeted therapies, particularly highly selective RET inhibitors, work by specifically blocking RET kinase activity, thereby suppressing tumor proliferation while minimizing off-target toxicity seen with older multikinase inhibitors. The advent of these therapies has significantly improved clinical outcomes, offering higher response rates, durable disease control, and better tolerability for patients with RET fusion-driven malignancies.
RET Fusion Targeted Therapies Epidemiology Segmentation
The RET fusion targeted therapies market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2020–2034 across the leading markets. The RET fusion targeted therapies target patient pool is segmented into:
RET Fusion Targeted Therapies Report Metrics
Details
Study Period
2020–2034
RET Fusion Targeted Therapies Report Coverage
7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Key Indications Covered in the Report
NSCLC, medullary thyroid cancer, and other cancers driven by RET fusions
RET Fusion Targeted Therapies Target Patient Pool Segmentation
Total Cases in Selected Indications for RET Fusion Targeted Therapies, Total Eligible Patient Pool in Selected Indications for RET Fusion Targeted Therapies, and Total Treated Cases in Selected Indications for RET Fusion Targeted Therapies
Key RET Fusion Targeted Therapies Companies
Merck & Co., Ellipses Pharma, Eli Lilly, Rigel Pharmaceuticals, and others
Key RET Fusion Targeted Therapies
Sacituzumab tirumotecan, EP0031, RETEVMO, GAVRETO, and others
Scope of the RET Fusion Targeted Therapies Market Report
Discover what's the status of Phase I/II/III RET fusion therapy clinical trials @ RET Fusion Targeted Therapies Clinical Trials
Table of Contents
1
RET Fusion Targeted Therapies Market Key Insights
2
RET Fusion Targeted Therapies Market Report Introduction
3
Executive Summary
4
Key Events
5
Market Forecast Methodology
6
RET Fusion Targeted Therapies Market Overview at a Glance in the 7MM
6.1
Market Share (%) Distribution by Indication in 2020
6.2
Market Share (%) Distribution by Indication in 2034
7
RET Fusion Targeted Therapies: Background and Overview
7.1
Introduction
7.2
Evolution of RET Fusion Targeted Therapies
7.3
Treatment
8
Target RET Fusion Targeted Therapies Patient Pool
8.1
Key Findings
8.2
Assumptions and Rationale: 7MM
8.3
Epidemiology Scenario in the 7MM
8.3.1
Total Cases in Selected Indications for RET Fusion Targeted Therapies in the 7MM
8.3.2
Total Eligible Patient Pool in Selected Indications for RET Fusion Targeted Therapies in the 7MM
8.3.3
Total Treated Cases in Selected Indications for RET Fusion Targeted Therapies in the 7MM
8.4
United States
8.4.1
Total Cases in Selected Indications for RET Fusion Targeted Therapies in the US
8.4.2
Total Eligible Patient Pool in Selected Indications for RET Fusion Targeted Therapies in the US
8.4.3
Total Treated Cases in Selected Indications for RET Fusion Targeted Therapies in the US
8.5
EU4 and the UK
8.6
Japan
9
Marketed RET Fusion Targeted Therapies
9.1
Key Competitors
9.2
GAVRETO (pralsetinib): Rigel Pharmaceuticals
9.2.1
Product Description
9.2.2
Regulatory Milestones
9.2.3
Other Developmental Activities
9.2.4
Clinical Development
9.2.5
Safety and Efficacy
9.3
RETEVMO (Selpercatinib): Eli Lilly
List of drugs to be continued in the final report...
10
Emerging RET Fusion Targeted Therapies
10.1
Key Competitors
10.2
Sacituzumab tirumotecan: Merck & Co.
10.2.1
Drug Description
10.2.2
Other Developmental Activity
10.2.3
Clinical Trial Information
10.2.4
Safety and Efficacy
10.2.5
Analyst's View
10.3
EP0031: Ellipses Pharma
List of drugs to be continued in the final report...
11
RET Fusion Targeted Therapies Market: the 7MM Analysis
11.1
Key Findings
11.2
RET Fusion Targeted Therapies Market Outlook
11.3
Attribute Analysis
11.4
Key RET Fusion Targeted Therapies Market Forecast Assumptions
11.5
Total Market Size of RET Fusion Targeted Therapies in the 7MM
11.6
The United States RET Fusion Targeted Therapies Market Size
11.6.1
Total Market Size of RET Fusion Targeted Therapies in the United States
11.6.2
Market Size of RET Fusion Targeted Therapies by Therapies in the United States
11.7
EU4 and the UK RET Fusion Targeted Therapies Market Size
11.8
Japan RET Fusion Targeted Therapies Market Size
12
RET Fusion Targeted Therapies Market Unmet Needs
13
RET Fusion Targeted Therapies Market SWOT Analysis
14
KOL Views on RET Fusion Targeted Therapies
15
RET Fusion Targeted Therapies Market Access and Reimbursement
15.1
United States
15.2
EU4 and the UK
15.3
Japan
16
Acronyms and Abbreviations
17
Bibliography
18
RET Fusion Targeted Therapies Market Report Methodology
Related Reports
Non-small Cell Lung Cancer Market
The NSCLC market size has undergone a revolutionary transformation over the last decade, driven by an increase in incident cases, the continuous adoption of approved therapies primarily immune checkpoint inhibitors, the anticipated introduction of premium-priced treatments, and growing awareness of mutations such as KRAS, BRAF, c-Met, and others. NSCLC is increasingly becoming a biomarker-driven market. EGFR is one of the profitable biomarker segments, with blockbuster therapies such as TAGRISSO. TAGRISSO is now the dominant EGFR inhibitor, selling nearly USD 6 billion annually. The non-small cell lung cancer market size is estimated to be ~USD 30 billion in the leading markets (the US, EU4, the UK, and Japan) in 2024. It is anticipated to grow with a significant CAGR during the study period (2020-2034). Leading NSCLC companies include Daiichi Sankyo, AstraZeneca, Gilead Sciences, BieGene, AbbVie, Roche, Merck, Novartis, Pfizer, Takeda Pharmaceuticals, Eli Lilly, BerGenBio, GlaxoSmithKline, and Duality biologics, among others.
Non-small Cell Lung Cancer Clinical Trial Analysis
Non-small Cell Lung Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-small cell lung cancer companies, including BridgeBio Pharma, Daiichi Sankyo, EMD Serono, Merck, BridgeBio Pharma, Abbvie, Pfizer, Eli Lilly and Company BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical, Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, among others.
Medullary Thyroid Cancer Market
Medullary Thyroid Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key medullary thyroid cancer companies, including Bayer HealthCare, TYK Medicines, Inc., Applied Pharmaceutical Science, CSPC ZhongQi Pharmaceutical Technology Co., Ltd, among others.
Antibody Drug Conjugates Market
Antibody Drug Conjugates Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key ADC companies, including AbbVie, Genmab, Daiichi Sankyo, AstraZeneca, Astellas, Roche, Pfizer (Seagen), Takeda, Ambrx, Daiichi Sankyo, Merck, Eisai, Bristol-Myers Squibb, Sanofi, NBE-Therapeutics, ImmunoGen, Inc., Seagen Inc., ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Sorrento Therapeutics, Inc., Peak Bio, Regeneron Pharmaceuticals, Asana BioSciences, Tanabe Research Laboratories USA, OBI Pharma, Navrogen, Inc., among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
SOURCE DelveInsight Business Research, LLP